ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | New York |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations | The Regents of the University of Michigan / Jolanta Grembecka, PhD | Reach Grants | 2022 | Michigan |
Epigenetic therapies to concurrently target DIPG tumor cells and harness the immune system | The Regents of the University of Michigan / Sriram Venneti, MD/PhD | R Accelerated Award Grants | 2022 | Michigan |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG | The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD | Reach Grants | 2022 | Michigan |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | Maryland |
Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma | University of Massachusetts Amherst / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD | Innovation Grants | 2022 | Massachusetts |
Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma | Dana-Farber Cancer Institute / Rani George, MD, PhD | Innovation Grants | 2022 | Massachusetts |
Blocking the Evil Messenger in MYCN-driven High-risk Neuroblastoma | Boston University / Hui Feng, Md, PhD | Innovation Grants | 2022 | Massachusetts |
Molecular circuitry of fibrolamellar carcinoma | Massachusetts General Hospital / Nabeel Bardeesy, PhD | Innovation Grants | 2022 | Massachusetts |
Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma | University of Massachusetts Chan Medical School / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD | Innovation Grants | 2022 | Massachusetts |